| In millions, except per share items | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 | Jun-30-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Benchtop Laboratory Equipment | 10.0 | 9.0 | 6.8 | 7.1 | 6.4 | 5.8 | 5.4 | 5.4 |
| Other | 1.4 | 0.7 | 1.0 | 3.1 | 2.1 | 2.4 | 4.1 | 2.4 |
| Total revenues | 11.4 | 9.8 | 7.8 | 10.2 | 8.5 | 8.1 | 9.6 | 7.8 |
| Revenue growth [+] | 16.6% | 25.6% | -23.7% | 20.3% | 4.1% | -15.1% | 22.3% | 15.5% |
| Benchtop Laboratory Equipment | 10.4% | 33.3% | -4.2% | 10.5% | 10.7% | 6.1% | 0.7% | 15.6% |
| Bioprocessing Systems | 94.0% | -26.9% | -23.4% | 95.2% | 127.0% | 156.0% | -5.7% | -36.1% |
| Cost of goods sold | 5.7 | 4.8 | 3.8 | 5.8 | 5.3 | 5.3 | 5.7 | 4.7 |
| Gross profit | 5.7 | 5.0 | 3.9 | 4.4 | 3.2 | 2.9 | 3.9 | 3.1 |
| Gross margin | 50.3% | 50.9% | 50.6% | 42.8% | 38.0% | 35.3% | 40.8% | 39.8% |
| Selling, general and administrative [+] | 10.1 | 8.1 | 3.5 | 3.1 | 2.7 | 2.6 | 3.1 | 2.7 |
| Sales and marketing | 4.3 | 4.0 | 1.2 | 1.1 | 1.0 | 0.9 | 1.4 | 1.0 |
| General and administrative | 5.8 | 4.0 | 2.3 | 1.9 | 1.7 | 1.7 | 1.7 | 1.7 |
| Research and development | 2.9 | 1.6 | 1.1 | 0.5 | 0.5 | 0.4 | 0.3 | 0.4 |
| EBITDA [+] | -6.6 | -4.5 | -0.5 | 1.0 | 0.3 | 0.2 | 0.9 | 0.4 |
| EBITDA growth | 47.5% | 786.8% | -148.6% | 244.9% | 23.0% | -72.5% | 112.1% | 190.1% |
| EBITDA margin | -57.7% | -45.6% | -6.5% | 10.1% | 3.5% | 3.0% | 9.2% | 5.3% |
| Depreciation and amortization | 0.7 | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 |
| EBIT [+] | -7.3 | -4.7 | -0.7 | 0.8 | 0.0 | -0.1 | 0.5 | 0.0 |
| EBIT growth | 54.3% | 609.7% | -185.5% | -14210.9% | -95.1% | -124.6% | -2824.4% | -85.8% |
| EBIT margin | -63.7% | -48.2% | -8.5% | 7.6% | -0.1% | -1.4% | 4.8% | -0.2% |
| Non-recurring items [+] | | | | | | 0.0 | 0.2 | |
| Asset impairment | | | | | | 0.0 | 0.2 | |
| Interest income, net [+] | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expense | | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 0.2 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other non-operating income | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -7.0 | -4.1 | -0.7 | 0.8 | 0.0 | -0.1 | 0.2 | 0.0 |
| Income taxes | -1.3 | -1.2 | -0.4 | 0.1 | 0.2 | -0.1 | 0.1 | 0.0 |
| Tax rate | 19.3% | 28.4% | 65.4% | 16.2% | 11564.3% | 50.5% | 24.3% | 219.2% |
| Earnings from continuing ops | -5.6 | -3.1 | -0.5 | 0.6 | -0.2 | -0.1 | 0.2 | 0.0 |
| Earnings from discontinued ops | | -0.6 | -0.2 | | | | | |
| Net income | -5.6 | -3.7 | -0.7 | 0.6 | -0.2 | -0.1 | 0.2 | 0.0 |
| Net margin | -49.5% | -37.6% | -9.0% | 6.3% | -1.9% | -0.9% | 1.7% | 0.1% |
| |
| Basic EPS [+] | ($0.85) | ($0.98) | ($0.30) | $0.43 | ($0.11) | ($0.05) | $0.11 | $0.01 |
| Growth | -12.7% | 225.8% | -169.3% | -502.2% | 120.6% | -143.8% | 1789.4% | -110.8% |
| Diluted EPS [+] | ($0.85) | ($0.98) | ($0.30) | $0.43 | ($0.11) | ($0.05) | $0.11 | $0.01 |
| Growth | -12.7% | 225.8% | -170.1% | -497.4% | 120.6% | -143.8% | 1791.3% | -110.8% |
| |
| |
| Shares outstanding (basic) [+] | 6.6 | 3.2 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| Growth | 108.1% | 110.5% | 1.4% | 0.0% | 0.2% | 0.1% | 0.7% | 6.7% |
| Shares outstanding (diluted) [+] | 6.6 | 3.2 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| Growth | 108.1% | 110.5% | 0.2% | 1.2% | 0.2% | 0.1% | 0.6% | 6.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |